174 related articles for article (PubMed ID: 30902875)
1. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of
Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L
J Nucl Med; 2019 Sep; 60(9):1253-1258. PubMed ID: 30902875
[TBL] [Abstract][Full Text] [Related]
2. Prospective, Multisite, International Comparison of
Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM
J Nucl Med; 2019 Jun; 60(6):794-800. PubMed ID: 30442757
[TBL] [Abstract][Full Text] [Related]
3. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
6.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
7. Detection Rate of
Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
[TBL] [Abstract][Full Text] [Related]
8. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
[TBL] [Abstract][Full Text] [Related]
9. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
10. Matched-Pair Comparison of
Rauscher I; Krönke M; König M; Gafita A; Maurer T; Horn T; Schiller K; Weber W; Eiber M
J Nucl Med; 2020 Jan; 61(1):51-57. PubMed ID: 31253741
[No Abstract] [Full Text] [Related]
11. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
[TBL] [Abstract][Full Text] [Related]
12.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
13. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
14. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
Bashir U; Tree A; Mayer E; Levine D; Parker C; Dearnaley D; Oyen WJG
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):901-907. PubMed ID: 30617554
[TBL] [Abstract][Full Text] [Related]
15. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
16. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
17. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of
Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
[TBL] [Abstract][Full Text] [Related]
19. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
20. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]